NAGE vs TBPH: fair value comparison
Niagen Bioscience, Inc. and Theravance Biopharma, Inc. · Updated 2026-10-19
NAGE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. TBPH is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, TBPH currently ranks higher by quality score.
| NAGE | TBPH | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $2.49 | $17.03 |
| 12-month range | $2.49–$7.60 | $13.57–$20.74 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #35 of 301 Healthcare | #33 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | — | Undervalued |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: NAGE fair value analysis · TBPH fair value analysis